EDITOX, cell tests to assess the impact of drugs on RNA editing and the adverse side effects they can generate in patients.
ALCEDIAG has developed EDITOX, a catalog of cell tests to mimic drugs impact on RNA editing in patients, primarily designed for the preclinical phases of drug development.
In the context of EDITOX, ALCEDIAG performs a series of in vitrotests, to study RNA editing modifications of various targets in different conditions (dosages, short and long term administration etc). As a following step, ALCEDIAG studies how RNA editing and its kinetics have been impacted in the different scenarios. EDITOX objective is to provide additional data about a drug mode of action, and more precisely to allow a deeper understanding of how a drug can impact RNA editing.
Moreover, the company proposes a proprietary cell test and process to anticipate and, as the case may be, prevent drugs adverse psychiatric side effects, such as depression and suicidal behavior. Using a dedicated cell line and proprietary biomarkers, ALCEDIAG has discovered a biological signature for drugs at risk to induce adverse psychiatric effects in patients. More than 300 molecules have been tested so far and the performances of the test show high specificity and sensitivity. Results are provided in the form of a risk assessment: “Low risk”, “Undefined risk” or “High risk”.
ALCEDIAG also proposes a service based on the analysis of RNA editing molecular interactions to reverse adverse side effects induced by the drug. The objective is to maintain drug curative possibilities while eliminating the risks of adverse psychiatric side effects. This service is aimed at pharmaceutical companies who are willing to “save” a molecule with exceptional curative potential. It optimizes the overall development costs, by preventing the discontinuation of research on drug candidates.
Thanks to EDITOX, ALCEDIAG aims firstly to complement and then finally replace tests for psychiatric adverse side effects which are currently performed on rodents. Animal testing, beyond the many ethical issues that surrounds it, has proved over the years to be of limited efficiency: several molecules which previously passed successfully the tests on rodents, have been later removed from the market after waves of depression or even suicidal behavior among the patients treated.